Ventricular Assist Device (VAD) Program

Mechanical Circulatory Support

Left ventricular assist device (LVAD) therapy has become more promising due to recent data that suggests improved survival and quality of life in patients with end stage heart failure. Our group is expanding the use of this new technology beyond patients who are waiting for transplant (‘bridge to transplant’) to patients who do not qualify for transplant but have an unacceptable quality of life on medical therapy (‘destination therapy’). At Stanford, we have the newest devices available, including the HeartMate II and HeartWare devices, in order to provide the best care for our patients.

Some patients with heart failure feel worse despite the best medical therapy, and require advanced treatments for heart failure. A VAD is a surgically implanted device that helps the heart pump blood to the rest of the body.

A VAD increases long-term survival, quality of life, and allows patients with heart failure to return home to an active lifestyle. Learn more by reading the VAD FAQ »

VAD Therapy

Why Stanford?

Stanford researchers were instrumental in the development of left ventricular assist device (LVAD) therapy, leading to the first successful bridge to transplant implant in 1984 at Stanford by Dr. Philip Oyer.

We offer LVAD as both a bridge to heart transplant in patients waiting for a heart, and destination VAD therapy (when transplant is not the best option).

Stanford is one of two destination therapy VAD programs in the Bay Area, with the highest volume in the Bay Area, and is one of seven in California.

The Stanford Experience

Comprehensive Treatment:

Individualized Treatment:

Cutting-Edge Research:

Also download our pre-LVAD teaching presentation to learn more about the procedure.

Stanford Medicine Resources:

Footer Links: